Bioaffinity Technologies Inc 's Cash & cash equivalent grew by 4.95 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Bioaffinity Technologies Inc 's Quick Ratio to 1.01, Quick Ratio remained below Bioaffinity Technologies Inc average.

Within Medical Laboratories industry 22 other companies have achieved higher Quick Ratio than Bioaffinity Technologies Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1560 to 1899.

Explain Quick Ratio?
How much Cash & cash equivalents BIAF�s has?
What are BIAF�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BIAF/financial-strength

https://api.csimarket.com/api/v1/companies/BIAF/fundamentals

https://api.csimarket.com/api/v1/companies/BIAF/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BIAF Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	7.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-66.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.01	Subscribe	Subscribe	Subscribe	Subscribe
BIAF's Total Ranking	# 1899	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-5.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	4.95 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 23
Healthcare Sector	# 644
Overall Market	# 1899

Quick Ratio Statistics
High	Average	Low
12.27	3.3	0.1
(Mar 31 2023)		(Dec 31 2021)

Financial Statements
Bioaffinity Technologies Inc 's Current Liabilities	$ 3 Millions	Visit BIAF's Balance sheet
Bioaffinity Technologies Inc 's Cash & cash equivalent	$ 3 Millions	Visit BIAF's Balance sheet
Source of BIAF's Sales		Visit BIAF's Sales by Geography

Cumulative Bioaffinity Technologies Inc 's Quick Ratio

BIAF's Quick Ratio for the trailling 12 Months

BIAF Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-1.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	44.96 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.29	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3926	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.56 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-26.06 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BIAF Financial Strength Comparisons >> Go to Compare BIAF Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $2.53 millions, cumulative Quick Ratio decreased to 1.29 below the Bioaffinity Technologies Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 35 other companies have achieved higher Quick Ratio than Bioaffinity Technologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2715 to 3926.

Explain Quick Ratio?
How much Cash & cash equivalents BIAF�s has?
What are BIAF�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 36
Healthcare Sector	# 892
Within the Market	# 3926

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.29	2.93	0.27
(Jun 30 2023)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions
Incyte Corporation	2.68	$ 3,854.572 Millions	$ 1,437.818 Millions
Exagen Inc	2.14	$ 28.092 Millions	$ 13.100 Millions
Biodesix Inc	1.99	$ 28.409 Millions	$ 14.248 Millions
Caredx Inc	1.80	$ 250.480 Millions	$ 138.975 Millions
Butterfly Network Inc	1.80	$ 122.301 Millions	$ 67.987 Millions
Sera Prognostics Inc	1.80	$ 44.089 Millions	$ 24.527 Millions
Radnet Inc	1.11	$ 797.880 Millions	$ 716.642 Millions
Bioaffinity Technologies Inc	1.01	$ 2.550 Millions	$ 2.533 Millions
Quest Diagnostics Inc	0.49	$ 893.000 Millions	$ 1,834.000 Millions
Medpace Holdings Inc	0.47	$ 705.315 Millions	$ 1,496.097 Millions
Ge Healthcare Technologies Inc	0.32	$ 2,826.000 Millions	$ 8,815.000 Millions
Grail Inc	0.31	$ 29.394 Millions	$ 94.332 Millions
Iqvia Holdings Inc	0.31	$ 2,422.000 Millions	$ 7,777.000 Millions
Fortrea Holdings Inc	0.22	$ 220.600 Millions	$ 983.300 Millions

Date modified: 2026-11-09T18:44:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.